{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:49:01Z","timestamp":1792511341448,"version":"4.5.0"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012669","name":"Natural Science Foundation Project of Chongqing","doi-asserted-by":"publisher","award":["cstc2018jscx-mszd0280"],"award-info":[{"award-number":["cstc2018jscx-mszd0280"]}],"id":[{"id":"10.13039\/501100012669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012149","name":"National Key Scientific Instrument and Equipment Development Projects of China","doi-asserted-by":"publisher","award":["21827812"],"award-info":[{"award-number":["21827812"]}],"id":[{"id":"10.13039\/501100012149","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejphar.2026.178546","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:04:08Z","timestamp":1768262648000},"page":"178546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Research progress on the mechanisms of action, pharmacological activities and clinical application of P-glycoprotein inhibitors"],"prefix":"10.1016","volume":"1015","author":[{"given":"Di","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifeng","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyue","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.178546_bib1","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1158\/1078-0432.CCR-08-0938","article-title":"A phase I study of the P-Glycoprotein antagonist tariquidar in combination with vinorelbine","volume":"15","author":"Abraham","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178546_bib2","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1016\/j.xphs.2020.07.027","article-title":"Dual formulation and interaction strategies to enhance the oral bioavailability of paclitaxel","volume":"109","author":"Al-Kandari","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejphar.2026.178546_bib3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/ags3.12440","article-title":"Recent developments in cancer research: expectations for a new remedy","volume":"5","author":"Ando","year":"2021","journal-title":"Ann. Gastroenterol. Surg."},{"key":"10.1016\/j.ejphar.2026.178546_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.critrevonc.2004.12.010","article-title":"Immunosuppressors and reversion of multidrug-resistance","volume":"56","author":"Aouali","year":"2005","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejphar.2026.178546_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1006046201497","article-title":"PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance","volume":"17","author":"Atadja","year":"1998","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejphar.2026.178546_bib6","doi-asserted-by":"crossref","first-page":"7147","DOI":"10.1007\/s00210-024-03743-y","article-title":"The \u201cspecific\u201d P-glycoprotein inhibitor zosuquidar (LY335979) also weakly inhibits human organic cation transporters","volume":"398","author":"Bajraktari-Sylejmani","year":"2025","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178546_bib7","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1124\/dmd.112.049148","article-title":"Tariquidar and elacridar are dose-dependently transported by P-Glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study","volume":"41","author":"Bankstahl","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejphar.2026.178546_bib8","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1021\/acs.biomac.7b00291","article-title":"Reversion of P-gp-Mediated drug resistance in ovarian carcinoma cells with PHPMA-zosuquidar conjugates","volume":"18","author":"Battistella","year":"2017","journal-title":"Biomacromolecules."},{"key":"10.1016\/j.ejphar.2026.178546_bib9","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2967\/jnumed.112.118232","article-title":"Interaction of 11 C-Tariquidar and 11 C-Elacridar with P-Glycoprotein and breast cancer resistance protein at the human blood\u2013brain barrier","volume":"54","author":"Bauer","year":"2013","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejphar.2026.178546_bib10","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/cpdd.1088","article-title":"P-Glycoprotein and breast cancer resistance protein transporter inhibition by cyclosporine and quinidine on the pharmacokinetics of oral rimegepant in healthy subjects","volume":"11","author":"Bhardwaj","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ejphar.2026.178546_bib11","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0006-2952(98)00007-0","article-title":"S9788 modulation of P-glycoprotein- and multidrug-related protein-mediated multidrug resistance by servier 9788 in doxorubicin-resistant MCF7 cells","volume":"56","author":"Bichat","year":"1998","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178546_bib12","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1007\/s11095-007-9278-4","article-title":"Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar","volume":"24","author":"Bihorel","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejphar.2026.178546_bib13","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000437","article-title":"Inhibition of the transmembrane transporter ABCB1 overcomes resistance to doxorubicin in patient-derived organoid models of HCC","volume":"8","author":"Blukacz","year":"2024","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.ejphar.2026.178546_bib14","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of multidrug resistance in cancer chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178546_bib15","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1039\/D3MD00612C","article-title":"Synthesis and evaluation of WK-X-34 derivatives as P-glycoprotein (P-gp\/ABCB1) inhibitors for reversing multidrug resistance","volume":"15","author":"Cao","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejphar.2026.178546_bib16","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3390\/molecules27030616","article-title":"Multidrug resistance (MDR): a widespread phenomenon in pharmacological therapies","volume":"27","author":"Catalano","year":"2022","journal-title":"Molecules."},{"key":"10.1016\/j.ejphar.2026.178546_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314667","article-title":"Regulation of P-Glycoprotein in the brain","volume":"23","author":"Chai","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178546_bib18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10637-005-1439-x","article-title":"A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer","volume":"23","author":"Chi","year":"2005","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejphar.2026.178546_bib19","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2174\/138161282005140214165212","article-title":"ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development","volume":"20","author":"Choi","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejphar.2026.178546_bib20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bcp.2015.12.007","article-title":"Drug\u2013protein hydrogen bonds govern the inhibition of the ATP hydrolysis of the multidrug transporter P-glycoprotein","volume":"101","author":"Chufan","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178546_bib21","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1182\/blood-2010-04-277269","article-title":"Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the eastern cooperative oncology group 3999","volume":"116","author":"Cripe","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.ejphar.2026.178546_bib22","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1126\/science.aav9406","article-title":"Mechanism of allosteric modulation of P-glycoprotein by transport substrates and inhibitors","volume":"364","author":"Dastvan","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2026.178546_bib23","first-page":"710","article-title":"Recent advances in the search of BCRP- and dual P-gp\/BCRP-based multidrug resistance modulators","volume":"2","author":"Dei","year":"2019","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.ejphar.2026.178546_bib24","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3390\/molecules22060871","article-title":"Natural products as alternative choices for P-Glycoprotein (P-gp) inhibition","volume":"22","author":"Dewanjee","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2026.178546_bib25","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.1158\/1078-0432.CCR-04-2316","article-title":"Phase I combining a P-Glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies","volume":"11","author":"Di\u00e9ras","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178546_bib26","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/14737140.7.4.447","article-title":"Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor","volume":"7","author":"Fox","year":"2007","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejphar.2026.178546_bib27","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00280-015-2845-1","article-title":"Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors","volume":"76","author":"Fox","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178546_bib28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/COC.0000000000001014","article-title":"A phase I trial of the ABCB1 inhibitor, oral valspodar, in combination with paclitaxel in patients with advanced solid tumors","volume":"46","author":"Fracasso","year":"2023","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.178546_bib29","doi-asserted-by":"crossref","first-page":"7220","DOI":"10.1158\/1078-0432.CCR-04-0452","article-title":"Phase I Study of docetaxel in combination with the P-Glycoprotein inhibitor, zosuquidar, in resistant malignancies","volume":"10","author":"Fracasso","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178546_bib30","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2967\/jnumed.115.157586","article-title":"Quantification of11 C-Laniquidar kinetics in the brain","volume":"56","author":"Froklage","year":"2015","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejphar.2026.178546_bib31","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/cncr.22492","article-title":"A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX\u2010710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer","volume":"109","author":"Gandhi","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejphar.2026.178546_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2024.1364494","article-title":"Membrane-assisted tariquidar access and binding mechanisms of human ATP-binding cassette transporter P-glycoprotein","volume":"11","author":"Gao","year":"2024","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejphar.2026.178546_bib33","first-page":"394","article-title":"Study on the mechanism of cyclosporin A reversing P-glycoprotein mediated multidrug resistance","author":"Gong","year":"2002","journal-title":"J West Chin Univ Med Sci."},{"key":"10.1016\/j.ejphar.2026.178546_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-32770-y","article-title":"Crown ethers reverse P-glycoprotein-mediated multidrug resistance in cancer cells","volume":"8","author":"Guberovi\u0107","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2026.178546_bib35","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1186\/s12967-025-06423-4","article-title":"Mitochondrial dysfunction fuels drug resistance in adult T-cell acute lymphoblastic leukemia","volume":"23","author":"Guo","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejphar.2026.178546_bib36","doi-asserted-by":"crossref","first-page":"4670","DOI":"10.1111\/bcp.14886","article-title":"Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: a randomised crossover pharmacokinetic study","volume":"87","author":"Jackson","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178546_bib37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/cn100078a","article-title":"The \u201cSpecific\u201d P-Glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for breast cancer Resistance protein (BCRP\/ABCG2)","volume":"2","author":"Kannan","year":"2011","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejphar.2026.178546_bib38","doi-asserted-by":"crossref","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","article-title":"Cancer treatment therapies: traditional to modern approaches to combat cancers","volume":"50","author":"Kaur","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ejphar.2026.178546_bib39","unstructured":"Kemper, E.M., van Zandbergen, A.E., Cleypool, C., Mos, H.A., Boogerd, W., Beijnen, J.H., van Tellingen, O., n.d. Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. Clin. Cancer Res. 1 July 2003; 9 (7): 2849\u20132855."},{"key":"10.1016\/j.ejphar.2026.178546_bib40","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.ejca.2004.01.024","article-title":"Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein","volume":"40","author":"Kemper","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejphar.2026.178546_bib41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2016.04.034","article-title":"Effect of HM30181 mesylate salt-loaded microcapsules on the oral absorption of paclitaxel as a novel P-glycoprotein inhibitor","volume":"506","author":"Kim","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejphar.2026.178546_bib42","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.2002.12.116","article-title":"Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-Glycoprotein inhibitor GF120918","volume":"20","author":"Kruijtzer","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.178546_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112153","article-title":"Verapamil and tangeretin enhances the M1 macrophages to M2 type in lipopolysaccharide-treated mice and inhibits the P-glycoprotein expression by downregulating STAT1\/STAT3 and upregulating SOCS3","volume":"133","author":"Kundu","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejphar.2026.178546_bib44","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s00280-004-0864-4","article-title":"Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093)","volume":"55","author":"Kuppens","year":"2005","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178546_bib45","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1158\/1078-0432.CCR-06-2414","article-title":"A phase I, randomized, Open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients","volume":"13","author":"Kuppens","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178546_bib46","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bcp.2016.08.013","article-title":"Cooperativity between verapamil and ATP bound to the efflux transporter P-glycoprotein","volume":"118","author":"Ledwitch","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178546_bib47","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1634\/theoncologist.2015-0202","article-title":"Phase I\/II study of weekly Oraxol for the second-line treatment of patients with metastatic or recurrent gastric cancer","volume":"20","author":"Lee","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.ejphar.2026.178546_bib107","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2007.14.9807","article-title":"Phase III Study of Valspodar (PSC 833) Combined With Paclitaxel and Carboplatin Compared With Paclitaxel and Carboplatin Alone in Patients With Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or Primary Peritoneal Cancer","volume":"26","author":"Lhomm\u00e9","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.178546_bib48","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1152\/physiol.00046.2006","article-title":"Structure and function of ABC transporters","volume":"22","author":"Linton","year":"2007","journal-title":"Physiology"},{"key":"10.1016\/j.ejphar.2026.178546_bib49","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.1993.11.9.1652","article-title":"Phase I\/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia","volume":"11","author":"List","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.178546_bib50","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41419-020-02998-6","article-title":"PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2026.178546_bib51","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.bcp.2014.10.006","article-title":"Tariquidar inhibits P-glycoprotein drug efflux but activates ATPase activity by blocking transition to an open conformation","volume":"92","author":"Loo","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178546_bib52","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.nucmedbio.2009.03.004","article-title":"Evaluation of [11c]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats","volume":"36","author":"Luurtsema","year":"2009","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejphar.2026.178546_bib53","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00280-022-04443-1","article-title":"A phase Ib study of oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies","volume":"90","author":"Ma","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178546_bib54","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00280-024-04656-6","article-title":"Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein phenotype","volume":"93","author":"Marcelletti","year":"2024","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178546_bib55","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/sj.bjp.0702807","article-title":"The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein","volume":"128","author":"Martin","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178546_bib56","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1158\/1078-0432.CCR-0914-3","article-title":"VX-710 (Biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-Glycoprotein, multidrug resistance protein, and breast cancer resistance protein","volume":"10","author":"Minderman","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178546_bib57","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.lfs.2018.10.048","article-title":"Structural and functional aspects of P-glycoprotein and its inhibitors","volume":"214","author":"Mollazadeh","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2026.178546_bib58","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/ijc.2910560523","article-title":"Verapamil decreases P-glycoprotein expression in multidrug-resistant human leukemic cell lines","volume":"56","author":"Muller","year":"1994","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2026.178546_bib59","first-page":"582","article-title":"MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft Models1","volume":"8","author":"Naito","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178546_bib60","doi-asserted-by":"crossref","DOI":"10.1006\/bbrc.1999.0245","article-title":"Direct interaction between a quinoline derivative, MS-209, and Multidrug resistance Protein (MRP) in human gastric cancer cells","volume":"255","author":"Nakamura","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2026.178546_bib61","unstructured":"Newman, M.J., Rodarte, J.C., Benbatoul, K.D., Romano, S.J., Zhang, C., Krane, S., Moran, E.J., Uyeda, R.T., Dixon, R., Guns, E.S., Mayer, L.D., n.d. Discovery and characterization of OC144-093, a novel inhibitor of P-Glycoprotein- mediated multidrug resistance. Cancer Res. 1 June 2000; 60 (11): 2964\u20132972."},{"key":"10.1016\/j.ejphar.2026.178546_bib62","article-title":"Oral etoposide and zosuquidar bioavailability in rats: effect of co-administration and in vitro-in vivo correlation of P-glycoprotein inhibition","volume":"3","author":"Nielsen","year":"2021","journal-title":"Int. J. Pharm. X"},{"key":"10.1016\/j.ejphar.2026.178546_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.137716","article-title":"Hydrazidomethyl starch as a pH-sensitive coating for magnetic core in tailored magnetic nanoparticles with selective doxorubicin release","volume":"283","author":"Nowak","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejphar.2026.178546_bib64","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3390\/ijms25063107","article-title":"Zosuquidar: an effective molecule for intracellular Ca2+ Fluo-3\/AMMeasurement in P-gp positive cells","volume":"25","author":"Pelegrinova","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178546_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123965","article-title":"Co-release of paclitaxel and encequidar from amorphous solid dispersions increase oral paclitaxel bioavailability in rats","volume":"654","author":"Petersen","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejphar.2026.178546_bib66","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF00877238","article-title":"In vitro andin vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative","volume":"10","author":"Pierr\u00e9","year":"1992","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejphar.2026.178546_bib67","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/bjc.1997.563","article-title":"Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer","volume":"76","author":"Punt","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejphar.2026.178546_bib68","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/cncr.21227","article-title":"Phase II study of tariquidar, a selective p\u2010glycoprotein inhibitor, in patients with chemotherapy\u2010resistant, advanced breast carcinoma","volume":"104","author":"Pusztai","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ejphar.2026.178546_bib69","doi-asserted-by":"crossref","first-page":"e943","DOI":"10.1016\/S2468-2667(23)00211-6","article-title":"National and subnational trends in cancer burden in China, 2005\u201320: an analysis of national mortality surveillance data","volume":"8","author":"Qi","year":"2023","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.ejphar.2026.178546_bib70","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1021\/acs.jmedchem.6b01787","article-title":"Design, synthesis, and pharmacological characterization of N-(4-(2 (6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)yl)ethyl)phenyl)quinazolin-4-amine derivatives: novel inhibitors reversing P-Glycoprotein-Mediated multidrug resistance","volume":"60","author":"Qiu","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.178546_bib71","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3389\/fchem.2019.00820","article-title":"Novel quinoline compound derivatives of NSC23925 as potent reversal agents against P-Glycoprotein-Mediated multidrug resistance","volume":"7","author":"Quan","year":"2019","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejphar.2026.178546_bib72","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00280-003-0573-4","article-title":"Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer","volume":"51","author":"Rago","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178546_bib73","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/jop.2018.0041","article-title":"Dose optimization based on population pharmacokinetic modeling of high-dose cyclosporine, a P-glycoprotein inhibitor, in combination with systemic chemotherapy in pediatric patients with retinoblastoma","volume":"34","author":"Ree","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2026.178546_bib74","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1521-6926(04)00080-5","article-title":"Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome","volume":"17","author":"Ross","year":"2004","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.ejphar.2026.178546_bib75","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.740","article-title":"Optimization of dose and route of administration of the P-glycoprotein inhibitor, valspodar (PSC-833) and the P-glycoprotein and breast cancer resistance protein dual-inhibitor, elacridar (GF120918) as dual infusion in rats","volume":"9","author":"Rowbottom","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.ejphar.2026.178546_bib76","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/jcph.651","article-title":"The effect of quinidine, a strong p\u2010glycoprotein inhibitor, on the pharmacokinetics and central nervous System distribution of naloxegol","volume":"56","author":"Ruan","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178546_bib77","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/JCO.21.02953","article-title":"Open-label, randomized, multicenter, phase III study comparing oral paclitaxel plus encequidar versus intravenous paclitaxel in patients with metastatic breast cancer","volume":"41","author":"Rugo","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.178546_bib78","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0304-3835(03)00270-2","article-title":"Effect of PSC 833, a potent inhibitor of P-glycoprotein, on the growth of astrocytoma cells in vitro","volume":"198","author":"Sadanand","year":"2003","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejphar.2026.178546_bib79","first-page":"215","article-title":"Dofequidar fumarate (MS-209) in combination with CAF for patients with breast cancer","volume":"13th","author":"Sei","year":"2005","journal-title":"Abstracts of the Program of the Annual Meeting of the Japanese Breast Cancer Society"},{"key":"10.1016\/j.ejphar.2026.178546_bib80","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1124\/jpet.107.127704","article-title":"Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells","volume":"324","author":"Shen","year":"2008","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2026.178546_bib81","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1021\/acs.jmedchem.0c01826","article-title":"Discovery of encequidar, first-in-class intestine specific P-glycoprotein inhibitor","volume":"64","author":"Smolinski","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.178546_bib82","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3390\/ijms26031124","article-title":"The role of elacridar, a P-gp inhibitor, in the Re-Sensitization of PAC-resistant ovarian cancer cell lines to cytotoxic drugs in 2D and 3D cell culture models","volume":"26","author":"Stasiak","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178546_bib83","doi-asserted-by":"crossref","first-page":"7972","DOI":"10.1038\/s41598-017-08062-2","article-title":"Targeting P-glycoprotein: investigation of piperine analogs for overcoming drug resistance in cancer","volume":"7","author":"Syed","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2026.178546_bib84","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s00259-001-0705-1","article-title":"Evaluation of MS-209, a novel multidrug-resistance-reversing agent, in tumour-bearing mice by technetium-99m-MIBI imaging","volume":"29","author":"Tatsumi","year":"2002","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejphar.2026.178546_bib85","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1146\/annurev-biochem-011520-105201","article-title":"Structural and mechanistic principles of ABC transporters","volume":"89","author":"Thomas","year":"2020","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejphar.2026.178546_bib86","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3892\/ijo.2023.5567","article-title":"Mechanism of multidrug resistance to chemotherapy mediated by P-glycoprotein","volume":"63","author":"Tian","year":"2023","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejphar.2026.178546_bib87","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1200\/JCO.1996.14.4.1173","article-title":"Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer","volume":"14","author":"Tolcher","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.178546_bib88","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/bloodadvances.2022008543","article-title":"Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL","volume":"7","author":"Torka","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejphar.2026.178546_bib89","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s002800050741","article-title":"Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors","volume":"41","author":"Tranchand","year":"1998","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178546_bib90","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1021\/acs.jmedchem.1c01272","article-title":"Discovery and characterization of potent dual P-Glycoprotein and CYP3A4 inhibitors: design, synthesis, Cryo-EM analysis, and biological evaluations","volume":"65","author":"Urgaonkar","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.178546_bib91","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0959-8049(02)00035-7","article-title":"Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933","volume":"38","author":"Van Zuylen","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejphar.2026.178546_bib92","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1006\/phrs.1999.0535","article-title":"P-GLYCOPROTEIN system as a determinant of drug interactions: the case of digoxin\u2013verapamil","volume":"40","author":"Verschraagen","year":"1999","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2026.178546_bib93","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1128\/AAC.01382-13","article-title":"Investigation of the functional role of P-Glycoprotein in limiting the oral bioavailability of lumefantrine","volume":"58","author":"Wahajuddin","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2026.178546_bib94","doi-asserted-by":"crossref","first-page":"84559","DOI":"10.18632\/oncotarget.19187","article-title":"Novel strategies to prevent the development of multidrug resistance (MDR) in cancer","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2026.178546_bib95","first-page":"141","article-title":"Drug resistance and combating drug resistance in cancer","volume":"2","author":"Wang","year":"2019","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.ejphar.2026.178546_bib96","series-title":"Drug Resistance in Leukemia and Lymphoma III, Advances in Experimental Medicine and Biology","first-page":"35","article-title":"Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-Glycoprotein (PGP)","author":"Wattel","year":"1999"},{"key":"10.1016\/j.ejphar.2026.178546_bib97","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/dmd.115.067785","article-title":"Tariquidar is an inhibitor and not a substrate of human and mouse P-glycoprotein","volume":"44","author":"Weidner","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejphar.2026.178546_bib98","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/fcp.12505","article-title":"NRF2\/ABCB1\u2010mediated efflux and PARP1\u2010mediated dampening of DNA damage contribute to doxorubicin resistance in chronic hypoxic HepG2 cells","volume":"34","author":"Xia","year":"2020","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178546_bib99","first-page":"33","article-title":"Experimental study on reversal of multidrug resistance in hepatocellular carcinoma by cyclosporin A","author":"Xiong","year":"2004","journal-title":"Chin J Exp Surg"},{"key":"10.1016\/j.ejphar.2026.178546_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117542","article-title":"Design, synthesis, and biological activity study of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives against multidrug resistance in Eca109\/VCR cells","volume":"291","author":"Xu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.178546_bib101","doi-asserted-by":"crossref","first-page":"626","DOI":"10.4143\/crt.2022.1058","article-title":"Trastuzumab combined with Irinotecan in patients with HER2-Positive metastatic colorectal cancer: a phase II single-arm Study and exploratory biomarker analysis","volume":"55","author":"Xu","year":"2023","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2026.178546_bib102","doi-asserted-by":"crossref","first-page":"234","DOI":"10.17305\/bjbms.2019.4073","article-title":"Valspodar-modulated chemotherapy in human ovarian cancer cells SK-OV-3 and MDAH-2774","volume":"19","author":"Zalewski","year":"2019","journal-title":"Biomol. Biomed."},{"key":"10.1016\/j.ejphar.2026.178546_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115258","article-title":"The effect and mechanistic study of encequidar on reversing the resistance of SW620\/AD300 cells to doxorubicin","volume":"205","author":"Zhang","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178546_bib104","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/bcpt.12596","article-title":"Measurement of rhodamine 123 in three\u2010dimensional organoids: a novel model for p\u2010glycoprotein inhibitor screening","volume":"119","author":"Zhang","year":"2016","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2026.178546_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106997","article-title":"Recent developments of P-glycoprotein inhibitors and its structure\u2013activity relationship (SAR) studies","volume":"143","author":"Zhao","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejphar.2026.178546_bib106","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202412649","article-title":"Highly potent and intestine specific p\u2010glycoprotein inhibitor to enable oral delivery of Taxol","volume":"63","author":"Zhou","year":"2024","journal-title":"Angew. Chem. Int. Ed."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926000282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926000282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T13:02:58Z","timestamp":1770123778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926000282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":107,"alternative-id":["S0014299926000282"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178546","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research progress on the mechanisms of action, pharmacological activities and clinical application of P-glycoprotein inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178546","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178546"}}